208 related articles for article (PubMed ID: 23860726)
1. Changes in the immune cell population and cell proliferation in peripheral blood after gemcitabine-based chemotherapy for pancreatic cancer.
Homma Y; Taniguchi K; Nakazawa M; Matsuyama R; Mori R; Takeda K; Ichikawa Y; Tanaka K; Endo I
Clin Transl Oncol; 2014 Mar; 16(3):330-5. PubMed ID: 23860726
[TBL] [Abstract][Full Text] [Related]
2. Circulating regulatory T cell subsets predict overall survival of patients with unresectable pancreatic cancer.
Liu C; Cheng H; Luo G; Lu Y; Jin K; Guo M; Ni Q; Yu X
Int J Oncol; 2017 Aug; 51(2):686-694. PubMed ID: 28714519
[TBL] [Abstract][Full Text] [Related]
3. Alterations in regulatory T cells and immune checkpoint molecules in pancreatic cancer patients receiving FOLFIRINOX or gemcitabine plus nab-paclitaxel.
Sams L; Kruger S; Heinemann V; Bararia D; Haebe S; Alig S; Haas M; Zhang D; Westphalen CB; Ormanns S; Metzger P; Werner J; Weigert O; von Bergwelt-Baildon M; Rataj F; Kobold S; Boeck S
Clin Transl Oncol; 2021 Nov; 23(11):2394-2401. PubMed ID: 33876417
[TBL] [Abstract][Full Text] [Related]
4. Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas.
Plate JM; Plate AE; Shott S; Bograd S; Harris JE
Cancer Immunol Immunother; 2005 Sep; 54(9):915-25. PubMed ID: 15782312
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine and S-1 combination chemotherapy versus gemcitabine alone for locally advanced and metastatic pancreatic cancer: a meta-analysis of randomized controlled trials in Asia.
Li Y; Sun J; Jiang Z; Zhang L; Liu G
J Chemother; 2015 Aug; 27(4):227-34. PubMed ID: 25790948
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine sensitizes pancreatic cancer cells to the CTLs antitumor response induced by BCG-stimulated dendritic cells via a Fas-dependent pathway.
Pei Q; Pan J; Ding X; Wang J; Zou X; Lv Y
Pancreatology; 2015; 15(3):233-9. PubMed ID: 25937078
[TBL] [Abstract][Full Text] [Related]
7. Distinct chemotherapy-associated anti-cancer immunity by myeloid cells inhibition in murine pancreatic cancer models.
Sakai Y; Miyazawa M; Komura T; Yamada T; Nasti A; Yoshida K; Takabatake H; Yamato M; Yamashita T; Yamashita T; Mizukoshi E; Okuzono M; Ho TTB; Kawaguchi K; Wada T; Honda M; Kaneko S
Cancer Sci; 2019 Mar; 110(3):903-912. PubMed ID: 30657234
[TBL] [Abstract][Full Text] [Related]
8. Combination of gemcitabine and anti-PD-1 antibody enhances the anticancer effect of M1 macrophages and the Th1 response in a murine model of pancreatic cancer liver metastasis.
Ho TTB; Nasti A; Seki A; Komura T; Inui H; Kozaka T; Kitamura Y; Shiba K; Yamashita T; Yamashita T; Mizukoshi E; Kawaguchi K; Wada T; Honda M; Kaneko S; Sakai Y
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33188035
[TBL] [Abstract][Full Text] [Related]
9. Successful adjuvant bi-weekly gemcitabine chemotherapy for pancreatic cancer without impairing patients' quality of life.
Toyama Y; Yoshida S; Saito R; Kitamura H; Okui N; Miyake R; Ito R; Son K; Usuba T; Nojiri T; Yanaga K
World J Surg Oncol; 2013 Jan; 11():3. PubMed ID: 23302293
[TBL] [Abstract][Full Text] [Related]
10. Low-dose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer.
Shevchenko I; Karakhanova S; Soltek S; Link J; Bayry J; Werner J; Umansky V; Bazhin AV
Int J Cancer; 2013 Jul; 133(1):98-107. PubMed ID: 23233419
[TBL] [Abstract][Full Text] [Related]
11. A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.
O'Neil BH; Scott AJ; Ma WW; Cohen SJ; Aisner DL; Menter AR; Tejani MA; Cho JK; Granfortuna J; Coveler L; Olowokure OO; Baranda JC; Cusnir M; Phillip P; Boles J; Nazemzadeh R; Rarick M; Cohen DJ; Radford J; Fehrenbacher L; Bajaj R; Bathini V; Fanta P; Berlin J; McRee AJ; Maguire R; Wilhelm F; Maniar M; Jimeno A; Gomes CL; Messersmith WA
Ann Oncol; 2015 Sep; 26(9):1923-1929. PubMed ID: 26091808
[TBL] [Abstract][Full Text] [Related]
12. Dendritic cell immunotherapy combined with gemcitabine chemotherapy enhances survival in a murine model of pancreatic carcinoma.
Ghansah T; Vohra N; Kinney K; Weber A; Kodumudi K; Springett G; Sarnaik AA; Pilon-Thomas S
Cancer Immunol Immunother; 2013 Jun; 62(6):1083-91. PubMed ID: 23604104
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine treatment enhanced the anti-tumor effect of cytokine induced killer cells by depletion of CD4
Zhao P; Zhu D; Zhang Z; Han B; Gao D; Wei X; Xie X; Li C; Sun W; Wang Q; Guo Q
Immunol Lett; 2017 Jan; 181():36-44. PubMed ID: 27867030
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of S100A4 mRNA in EUS-FNA specimens for the assessment of chemosensitivity to gemcitabine from patients with unresectable pancreatic cancer.
Ma G; Sun Y; Fu S
Int J Clin Exp Pathol; 2015; 8(10):13284-8. PubMed ID: 26722531
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy of gemcitabine-based chemotherapy on advanced pancreatic cancer].
Gong JF; Zhang XD; Li J; Di LJ; Jin ML; Shen L
Ai Zheng; 2007 Aug; 26(8):890-4. PubMed ID: 17697554
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine as first-line chemotherapy in elderly patients with unresectable pancreatic carcinoma.
Yamagishi Y; Higuchi H; Izumiya M; Sakai G; Iizuka H; Nakamura S; Adachi M; Hozawa S; Takaishi H; Hibi T
J Gastroenterol; 2010 Nov; 45(11):1146-54. PubMed ID: 20549255
[TBL] [Abstract][Full Text] [Related]
17. [Gemcitabine augments major histocompatibility complex class I-related chain A expression in pancreatic cancer].
Miyashita T; Tajima H; Shoji M; Nakanuma S; Sakai S; Makino I; Hayashi H; Nakagawara H; Takamura H; Kitagawa H; Ohta T
Gan To Kagaku Ryoho; 2013 Nov; 40(12):1600-2. PubMed ID: 24393861
[TBL] [Abstract][Full Text] [Related]
18. Suppressive effects of gemcitabine plus cisplatin chemotherapy on regulatory T cells in nonsmall-cell lung cancer.
Chen C; Chen Z; Chen D; Zhang B; Wang Z; Le H
J Int Med Res; 2015 Apr; 43(2):180-7. PubMed ID: 25659373
[TBL] [Abstract][Full Text] [Related]
19. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate.
Rocha Lima CM; Green MR; Rotche R; Miller WH; Jeffrey GM; Cisar LA; Morganti A; Orlando N; Gruia G; Miller LL
J Clin Oncol; 2004 Sep; 22(18):3776-83. PubMed ID: 15365074
[TBL] [Abstract][Full Text] [Related]
20. Surgical resection deteriorates gemcitabine-induced leukopenia in pancreatic cancer.
Onoue M; Terada T; Okuda M; Fujimoto K; Doi R; Imamura M; Inui K
Int J Clin Oncol; 2004 Jun; 9(3):174-8. PubMed ID: 15221601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
